肾康栓联合肾衰宁片治疗慢性肾功能衰竭的疗效观察

目的探究肾康栓联合肾衰宁片治疗慢性肾功能衰竭的临床疗效。方法收集2013年3月—2015年2月到重庆市永川区中医院肾病科就诊的慢性肾功能衰竭患者64例,随机分为对照组和治疗组,每组各32例。对照组在常规治疗前提下口服肾衰宁片,5片/次,3次/d。治疗组在对照组治疗基础上直肠给予肾康栓,5粒/d,早、中、晚各1粒,剩余2粒于患者入睡前使用。两组均连续治疗45 d。观察两组的临床疗效,同时比较两组治疗前后血尿素氮(BUN)、血肌酐(Scr)、内生肌酐清除率(Ccr)、24 h尿蛋白(24 h Upm)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为62.5%、75.0%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者BUN、Scr、24 h Upm均较治疗前显著降低,Ccr显著升高,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标改善程度优于对照组,两组比较差异有统计学意义(P0.05)。对照组和治疗组不良反应发生率分别为9.36%、6.25%,两组比较差异无统计学意义。结论肾康栓联合肾衰宁片治疗慢性肾功能衰竭的临床疗效较好,可改善肾功能相关指标,且不良反应发生率较低,具有一定的临床推广应用价值。

Clinical observation of Shenkang Suppository combined with Shenshuaining Tablets in treatment of chronic renal failure

Objective To explore the clinical effect of Shenkang Suppository combined with Shenshuaining Tablets in treatment of chronic renal failure. Methods Patients (64 cases) with chronic renal failure in Traditional Chinese Medicine Hospital of Yongchuan District in Chongqing from March 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 32 cases. The patients in the control group were po administered with Shenshuaining Tablets on the basis of routine therapy, 5 tablets/time, three times daily. The patients in the treatment group were given Shenkang Suppository by rectum on the basis of control group, 5 grains/d, early, middle and late each 1 grain, and the remaining 2 grains were used before sleeping. The patients in two groups were treated for 45 d. After treatment, the clinical efficacy were evaluated, and the changes of BUN, Scr, Ccr, and 24 h Upm before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 62.5% and 75.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, BUN, Scr and 24 h Upm in two groups were significantly decreased, Ccr was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The adverse reactions incidences in control and treatment groups were 9.36% and 6.25%, and there was no statistical significance between the two groups. Conclusion Shenkang Suppository combined with Shenshuaining Tablets has clinical curative effect in treatment of chronic renal failure, and can improve indicators related renal function with a lower incidence of adverse reactions, which has a certain clinical application value.